A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Status:
Terminated
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
This study is to evaluate efficacy and safety of Imatinib in two groups of patients; all
patients should be diagnosed less than 3 months as chronic myeloid leukemia in a chronic
phase. The group A, the reference group, will have 10% or less than 10% of the BCR-ABL level
after three month dosing and be maintained their dose of 400mg/day. On the other hand, the
group B, will have more than 10% and the dose will be increased from 400mg/day to 600mg/day.
The superiority of the group B will be proved by evaluating the MMR rate of these two groups
after 12 months of administeration of Imatinib.